Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Apr 15;101(8):1699–1707. doi: 10.1172/JCI2166

The full induction of human apoprotein A-I gene expression by the experimental nephrotic syndrome in transgenic mice depends on cis-acting elements in the proximal 256 base-pair promoter region and the trans-acting factor early growth response factor 1.

M Zaiou 1, N Azrolan 1, T Hayek 1, H Wang 1, L Wu 1, M Haghpassand 1, B Cizman 1, M P Madaio 1, J Milbrandt 1, J B Marsh 1, J L Breslow 1, E A Fisher 1
PMCID: PMC508752  PMID: 9541501

Abstract

To identify molecular factors regulating apo A-I production in vivo, we induced in transgenic mice the experimental nephrotic syndrome, which results in elevated levels of HDL cholesterol (HDL-C), plasma apo A-I, and hepatic apo A-I mRNA. Human (h) apo A-I transgenic mice with different length 5' flanking sequences (5.5 or 0.256 kb, the core promoter for hepatic-specific basal expression) were injected with nephrotoxic (NTS) or control serum. With nephrosis, there were comparable (greater than twofold) increases in both lines of HDL-C, h-apo A-I, and hepatic h-apo A-I mRNA, suggesting that cis-acting elements regulating induced apo A-I gene expression were within its core promoter. Hepatic nuclear extracts from control and nephrotic mice footprinted the core promoter similarly, implying that the same elements regulated basal and induced expression. Hepatic mRNA levels for hepatocyte nuclear factor (HNF) 4 and early growth response factor (EGR) 1, trans-acting factors that bind to the core promoter, were measured: HNF4 mRNA was not affected, but that of EGR-1 was elevated approximately fivefold in the nephrotic group. EGR-1 knockout (EGR1-KO) mice or mice expressing EGR-1 were injected with either NTS or control serum. Levels of HDL-C, apo A-I, and hepatic apo A-I mRNA were lowest in nonnephrotic EGR1-KO mice and highest in nephrotic mice expressing EGR-1. Although in EGR1-KO mice HDL-C, apo A-I, and apo A-I mRNA levels also increased after NTS injection, they were approximately half of those in the nephrotic EGR-1-expressing mice. We conclude that in this model, basal and induced apo A-I gene expression in vivo are regulated by the trans-acting factor EGR-1 and require the same cis-acting elements in the core promoter.

Full Text

The Full Text of this article is available as a PDF (383.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azrolan N., Breslow J. L. A solution hybridization/RNase protection assay with riboprobes to determine absolute levels of apoB, A-I, and E mRNA in human hepatoma cell lines. J Lipid Res. 1990 Jun;31(6):1141–1146. [PubMed] [Google Scholar]
  2. Blom van Assendelft G., Hanscombe O., Grosveld F., Greaves D. R. The beta-globin dominant control region activates homologous and heterologous promoters in a tissue-specific manner. Cell. 1989 Mar 24;56(6):969–977. doi: 10.1016/0092-8674(89)90630-2. [DOI] [PubMed] [Google Scholar]
  3. Burkey B. F., France D., Wang H., Ma X., Brand B., Abuhani C., Diffenderfer M. R., Marsh J. B., Paterniti J. R., Jr, Fisher E. A. Overexpression of human apolipoprotein A-I in transgenic rats and the hyperlipoproteinemia associated with experimental nephrosis. J Lipid Res. 1995 Jul;36(7):1463–1473. [PubMed] [Google Scholar]
  4. Calandra S., Tarugi P. Synthesis and secretion of apolipoprotein A-I. Biochem Soc Trans. 1993 May;21(2):493–499. doi: 10.1042/bst0210493. [DOI] [PubMed] [Google Scholar]
  5. Castelli W. P., Garrison R. J., Wilson P. W., Abbott R. D., Kalousdian S., Kannel W. B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986 Nov 28;256(20):2835–2838. [PubMed] [Google Scholar]
  6. Cereghini S. Liver-enriched transcription factors and hepatocyte differentiation. FASEB J. 1996 Feb;10(2):267–282. [PubMed] [Google Scholar]
  7. Chen W. S., Manova K., Weinstein D. C., Duncan S. A., Plump A. S., Prezioso V. R., Bachvarova R. F., Darnell J. E., Jr Disruption of the HNF-4 gene, expressed in visceral endoderm, leads to cell death in embryonic ectoderm and impaired gastrulation of mouse embryos. Genes Dev. 1994 Oct 15;8(20):2466–2477. doi: 10.1101/gad.8.20.2466. [DOI] [PubMed] [Google Scholar]
  8. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  9. Couser W. G., Darby C., Salant D. J., Adler S., Stilmant M. M., Lowenstein L. M. Anti-GBM antibody-induced proteinuria in isolated perfused rat kidney. Am J Physiol. 1985 Aug;249(2 Pt 2):F241–F250. doi: 10.1152/ajprenal.1985.249.2.F241. [DOI] [PubMed] [Google Scholar]
  10. Davies R. W., Staprans I., Hutchison F. N., Kaysen G. A. Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest. 1990 Aug;86(2):600–605. doi: 10.1172/JCI114750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Elshourbagy N. A., Boguski M. S., Liao W. S., Jefferson L. S., Gordon J. I., Taylor J. M. Expression of rat apolipoprotein A-IV and A-I genes: mRNA induction during development and in response to glucocorticoids and insulin. Proc Natl Acad Sci U S A. 1985 Dec;82(23):8242–8246. doi: 10.1073/pnas.82.23.8242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Francone O. L., Haghpassand M., Bennett J. A., Royer L., McNeish J. Expression of human lecithin:cholesterol acyltransferase in transgenic mice: effects on cholesterol efflux, esterification, and transport. J Lipid Res. 1997 Apr;38(4):813–822. [PubMed] [Google Scholar]
  13. Fraser J. D., Keller D., Martinez V., Santiso-Mere D., Straney R., Briggs M. R. Utilization of recombinant adenovirus and dominant negative mutants to characterize hepatocyte nuclear factor 4-regulated apolipoprotein AI and CIII expression. J Biol Chem. 1997 May 23;272(21):13892–13898. doi: 10.1074/jbc.272.21.13892. [DOI] [PubMed] [Google Scholar]
  14. Gashler A., Sukhatme V. P. Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. Prog Nucleic Acid Res Mol Biol. 1995;50:191–224. doi: 10.1016/s0079-6603(08)60815-6. [DOI] [PubMed] [Google Scholar]
  15. Gordon D. J., Knoke J., Probstfield J. L., Superko R., Tyroler H. A. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. Circulation. 1986 Dec;74(6):1217–1225. doi: 10.1161/01.cir.74.6.1217. [DOI] [PubMed] [Google Scholar]
  16. Gorski K., Carneiro M., Schibler U. Tissue-specific in vitro transcription from the mouse albumin promoter. Cell. 1986 Dec 5;47(5):767–776. doi: 10.1016/0092-8674(86)90519-2. [DOI] [PubMed] [Google Scholar]
  17. Haddad I. A., Ordovas J. M., Fitzpatrick T., Karathanasis S. K. Linkage, evolution, and expression of the rat apolipoprotein A-I, C-III, and A-IV genes. J Biol Chem. 1986 Oct 5;261(28):13268–13277. [PubMed] [Google Scholar]
  18. Hayek T., Chajek-Shaul T., Walsh A., Azrolan N., Breslow J. L. Probucol decreases apolipoprotein A-I transport rate and increases high density lipoprotein cholesteryl ester fractional catabolic rate in control and human apolipoprotein A-I transgenic mice. Arterioscler Thromb. 1991 Sep-Oct;11(5):1295–1302. doi: 10.1161/01.atv.11.5.1295. [DOI] [PubMed] [Google Scholar]
  19. Hayek T., Ito Y., Azrolan N., Verdery R. B., Aalto-Setälä K., Walsh A., Breslow J. L. Dietary fat increases high density lipoprotein (HDL) levels both by increasing the transport rates and decreasing the fractional catabolic rates of HDL cholesterol ester and apolipoprotein (Apo) A-I. Presentation of a new animal model and mechanistic studies in human Apo A-I transgenic and control mice. J Clin Invest. 1993 Apr;91(4):1665–1671. doi: 10.1172/JCI116375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kardassis D., Laccotripe M., Talianidis I., Zannis V. Transcriptional regulation of the genes involved in lipoprotein transport. The role of proximal promoters and long-range regulatory elements and factors in apolipoprotein gene regulation. Hypertension. 1996 Apr;27(4):980–1008. doi: 10.1161/01.hyp.27.4.980. [DOI] [PubMed] [Google Scholar]
  21. Kilbourne E. J., Widom R., Harnish D. C., Malik S., Karathanasis S. K. Involvement of early growth response factor Egr-1 in apolipoprotein AI gene transcription. J Biol Chem. 1995 Mar 24;270(12):7004–7010. doi: 10.1074/jbc.270.12.7004. [DOI] [PubMed] [Google Scholar]
  22. Lee S. L., Sadovsky Y., Swirnoff A. H., Polish J. A., Goda P., Gavrilina G., Milbrandt J. Luteinizing hormone deficiency and female infertility in mice lacking the transcription factor NGFI-A (Egr-1). Science. 1996 Aug 30;273(5279):1219–1221. doi: 10.1126/science.273.5279.1219. [DOI] [PubMed] [Google Scholar]
  23. Lee S. L., Tourtellotte L. C., Wesselschmidt R. L., Milbrandt J. Growth and differentiation proceeds normally in cells deficient in the immediate early gene NGFI-A. J Biol Chem. 1995 Apr 28;270(17):9971–9977. doi: 10.1074/jbc.270.17.9971. [DOI] [PubMed] [Google Scholar]
  24. Marsh J. B., Diffenderfer M. R., Fisher E. A., Sowden M., Dong M., Paterniti J. R., Burkey B. F. Effect of experimental nephrosis on hepatic lipoprotein secretion and urinary lipoprotein excretion in rats expressing the human apolipoprotein A-I gene. J Lipid Res. 1996 May;37(5):1113–1124. [PubMed] [Google Scholar]
  25. Marsh J. B. Lipoprotein metabolism in experimental nephrosis. Proc Soc Exp Biol Med. 1996 Nov;213(2):178–186. doi: 10.3181/00379727-213-44048. [DOI] [PubMed] [Google Scholar]
  26. Marsh J. B. Lipoprotein metabolism in experimental nephrosis. J Lipid Res. 1984 Dec 15;25(13):1619–1623. [PubMed] [Google Scholar]
  27. Marshall J. F., Apostolopoulos J. J., Brack C. M., Howlett G. J. Regulation of apolipoprotein gene expression and plasma high-density lipoprotein composition in experimental nephrosis. Biochim Biophys Acta. 1990 Feb 23;1042(3):271–279. doi: 10.1016/0005-2760(90)90153-o. [DOI] [PubMed] [Google Scholar]
  28. Maxam A. M., Gilbert W. Sequencing end-labeled DNA with base-specific chemical cleavages. Methods Enzymol. 1980;65(1):499–560. doi: 10.1016/s0076-6879(80)65059-9. [DOI] [PubMed] [Google Scholar]
  29. Miller J. C., Barth R. K., Shaw P. H., Elliott R. W., Hastie N. D. Identification of a cDNA clone for mouse apoprotein A-1 (apo A-1) and its use in characterization of apo A-1 mRNA expression in liver and small intestine. Proc Natl Acad Sci U S A. 1983 Mar;80(6):1511–1515. doi: 10.1073/pnas.80.6.1511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Miller N. E. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J. 1987 Feb;113(2 Pt 2):589–597. doi: 10.1016/0002-8703(87)90638-7. [DOI] [PubMed] [Google Scholar]
  31. Nathans D., Lau L. F., Christy B., Hartzell S., Nakabeppu Y., Ryder K. Genomic response to growth factors. Cold Spring Harb Symp Quant Biol. 1988;53(Pt 2):893–900. doi: 10.1101/sqb.1988.053.01.102. [DOI] [PubMed] [Google Scholar]
  32. Papazafiri P., Ogami K., Ramji D. P., Nicosia A., Monaci P., Cladaras C., Zannis V. I. Promoter elements and factors involved in hepatic transcription of the human ApoA-I gene positive and negative regulators bind to overlapping sites. J Biol Chem. 1991 Mar 25;266(9):5790–5797. [PubMed] [Google Scholar]
  33. Peters J. M., Hennuyer N., Staels B., Fruchart J. C., Fievet C., Gonzalez F. J., Auwerx J. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem. 1997 Oct 24;272(43):27307–27312. doi: 10.1074/jbc.272.43.27307. [DOI] [PubMed] [Google Scholar]
  34. Plump A. S., Scott C. J., Breslow J. L. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9607–9611. doi: 10.1073/pnas.91.20.9607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Reisher S. R., Fisher E. A., Feinstein S. I. Rabbit and rat liver nuclei both contain proteins which bind to the regions controlling apolipoprotein A-I gene expression. Eur J Biochem. 1993 Aug 15;216(1):247–253. doi: 10.1111/j.1432-1033.1993.tb18139.x. [DOI] [PubMed] [Google Scholar]
  36. Schrijver G., Assmann K. J., Bogman M. J., Robben J. C., de Waal R. M., Koene R. A. Antiglomerular basement membrane nephritis in the mouse. Study on the role of complement in the heterologous phase. Lab Invest. 1988 Oct;59(4):484–491. [PubMed] [Google Scholar]
  37. Sorci-Thomas M., Prack M. M., Dashti N., Johnson F., Rudel L. L., Williams D. L. Apolipoprotein (apo) A-I production and mRNA abundance explain plasma apoA-I and high density lipoprotein differences between two nonhuman primate species with high and low susceptibilities to diet-induced hypercholesterolemia. J Biol Chem. 1988 Apr 15;263(11):5183–5189. [PubMed] [Google Scholar]
  38. Sun X., Jones H., Jr, Joles J. A., van Tol A., Kaysen G. A. Apolipoprotein gene expression in analbuminemic rats and in rats with Heymann nephritis. Am J Physiol. 1992 May;262(5 Pt 2):F755–F761. doi: 10.1152/ajprenal.1992.262.5.F755. [DOI] [PubMed] [Google Scholar]
  39. Tarugi P., Calandra S., Chan L. Changes in apolipoprotein A-I mRNA level in the liver of rats with experimental nephrotic syndrome. Biochim Biophys Acta. 1986 Oct 16;868(1):51–61. doi: 10.1016/0167-4781(86)90086-2. [DOI] [PubMed] [Google Scholar]
  40. Vu-Dac N., Gervois P., Grötzinger T., De Vos P., Schoonjans K., Fruchart J. C., Auwerx J., Mariani J., Tedgui A., Staels B. Transcriptional regulation of apolipoprotein A-I gene expression by the nuclear receptor RORalpha. J Biol Chem. 1997 Sep 5;272(36):22401–22404. doi: 10.1074/jbc.272.36.22401. [DOI] [PubMed] [Google Scholar]
  41. Walsh A., Azrolan N., Wang K., Marcigliano A., O'Connell A., Breslow J. L. Intestinal expression of the human apoA-I gene in transgenic mice is controlled by a DNA region 3' to the gene in the promoter of the adjacent convergently transcribed apoC-III gene. J Lipid Res. 1993 Apr;34(4):617–623. [PubMed] [Google Scholar]
  42. Walsh A., Ito Y., Breslow J. L. High levels of human apolipoprotein A-I in transgenic mice result in increased plasma levels of small high density lipoprotein (HDL) particles comparable to human HDL3. J Biol Chem. 1989 Apr 15;264(11):6488–6494. [PubMed] [Google Scholar]
  43. Widom R. L., Ladias J. A., Kouidou S., Karathanasis S. K. Synergistic interactions between transcription factors control expression of the apolipoprotein AI gene in liver cells. Mol Cell Biol. 1991 Feb;11(2):677–687. doi: 10.1128/mcb.11.2.677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Zolfaghari R., Harrison E. H., Han J. H., Rutter W. J., Fisher E. A. Tissue and species differences in bile salt-dependent neutral cholesteryl ester hydrolase activity and gene expression. Arterioscler Thromb. 1992 Mar;12(3):295–301. doi: 10.1161/01.atv.12.3.295. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES